Citations

Clear

41 citation(s) found for "Langman, L".

Urine Drug Testing: Service Models and Laboratory Practices to Meet Clinical Care Needs
Stefan, Cristiana , Zhou, Janet R. , Franssen, Eric J. F. , Langman, Loralie J., Fu, Lei , Fu, Lei , Jung, Benjamin

Mayo Clinic

Therapeutic Drug Monitoring | February 23, 2026 | Volume: 48 | Issue: 2 | Pages: 185-195

10.1097/ftd.0000000000001428 | PMID 41729621 Get It

Abstract: Urine drug testing (UDT) is an important laboratory tool utilized in various healthcare settings to identify drug or toxic exposures. It has wide clinical applications, including but not limited to detecting substance misuse, monitoring treatment effectiveness and compliance, and identifying substances in affected patients. Depending on the clinical care setting and patient population, the UDT service model and practice are important decisions by the clinical laboratory to meet the needs of the healthcare providers. In addition, clinical laboratories must appreciate the testing process and unique aspects of this toxicology test, from specimen collection and integrity, testing methods, to the result reporting and interpretation. Each phase has specific quality requirements to ensure the accuracy and appropriate interpretation of results. This review aims to summarize the preanalytical, analytical, and postanalytical considerations of clinical laboratories when implementing the test or providing support to clinicians in point-of-care settings. To bring awareness of the limitations inherent to different analytical methodologies, this review discusses important considerations and presents the current gaps, opportunities, and recommendations for quality improvement and standardization. This article may serve as a framework for clinical laboratory directors and other laboratory professionals to review their current provision of UDT and provide recommendations on various important aspects when considering changes to the test service models to meet their local clinical needs, including when introducing new test methods. It may also help physicians and healthcare providers appreciate the complexities of UDT and recognize the challenges in clinical interpretation.
DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping
Moyer, A. M., Lundquist, Emma, Thoreson, Emily , Kluge, Michelle L. , Kotzer, Katrina E. , Love, Elyse M, Glessner, Heather L, Arneson, Sarah, Langman, Loralie J., Baudhuin, Linnea M. , Black, John Logan, Moyer, AM , Thoreson, Emily K, Arneson, Sarah K, Lundquist, Emma L., Love, Elyse M., Glessner, Heather Dean, Black, John L.

Mayo Clinic

Clinical Chemistry | January 13, 2026 | Volume: 72 | Issue: 6 | Pages: 662-669

10.1093/clinchem/hvag007 | PMID 41802113 Get It

Abstract Background DPYD testing can identify patients at risk for severe toxicity when a standard fluoropyrimidine antineoplastic dose is prescribed. Sequencing-based methods detect rare variants, which require classification. Methods DPYD sequencing results over a 9-year period through to 2024 were analyzed. The dataset was filtered to calculate the positive test rate for different genotyping strategies, including targeted analysis of the Association for Molecular Pathology (AMP) Tier 1 and 2 recommended alleles, and as compared to sequencing. Variant classifications based on the laboratory’s clinical protocol were compared to ClinVar classifications and designations by the Clinical Pharmacogenetics Implementation Consortium (CPIC) expert panel. Results A DPYD variant was reported in 12.79% (896/7003) of those tested, with 2.53% (170/7003) of all reports including a variant of uncertain significance. Had only AMP Tier 1 or both Tier 1 and 2 been tested, 9.30% and 9.44% of patients would have received a positive report, respectively. Among the 281 unique, non-Tier 1/Tier 2 variants encountered during sequencing, >80% were not classified by the CPIC expert panel, while >48% were not reported in ClinVar. Variant classifications by our laboratory and those in ClinVar were generally concordant with the CPIC expert panel, despite the lack of a standardized classification system. Conclusions While AMP Tier 1 genotyping would have identified most patients at risk for fluoropyrimidine toxicity, sequencing is more comprehensive, identifying 26% more reportable variants compared to targeted genotyping. A standard framework for pharmacogenomic variant classification could facilitate consistent variant classification and a transition from targeted genotyping to sequencing.
Pharmacogenomic Testing: Strategies and Technical Considerations for Clinical Laboratories
Ji, Yuan , Brunk, Lindsey, Bove, Betsy, Danyal, Karamatullah, Langman, Loralie J., Mot, Nicole, Mróz, Paweł , Natowicz, Marvin R. , Shirts, Brian, Smock, Kristi J. , Zhang, Bing , Moyer, Ann M. , Bove, Betsy, Mroz, Pawel, Reddi, Honey V. , Shirts, Brian, Wool, Geoffrey D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 22, 2025 | Volume: 150 | Issue: 5 | Pages: 339-353

10.5858/arpa.2025-0179-cp | PMID 41270809 Get It

Context.— Clinical laboratories are increasingly implementing pharmacogenomic (PGx) testing. Although PGx is similar to genetic testing for other indications, there are unique aspects that laboratories should consider. Objective.— To aid clinical laboratories that are implementing clinical PGx testing by describing characteristics of PGx test design and validation, as well as approaches to reporting. Resources that are useful for clinical laboratories performing PGx testing will be highlighted. Design.— The College of American Pathologists formed a workgroup composed of laboratorians with expertise in clinical PGx testing. The workgroup included representatives from the Association for Molecular Pathology and the American College of Medical Genetics and Genomics. The workgroup reviewed pertinent literature, as well as experience from proficiency testing and from members’ laboratories. Results.— The workgroup recommends that laboratories implementing PGx consider the following concepts: testing platform, test design (ie, selection of pharmacogenes and variants/alleles), use of reference materials during test development and as controls during clinical runs, star allele and standard nomenclature systems, translations from genotype to predicted phenotype, and considerations for result reporting including making medication recommendations. The workgroup provides considerations when using report vendors, emphasizing the clinical laboratory’s role and responsibility when implementing such reporting tools from vendors. Conclusions.— Clinical laboratories should be familiar with the fundamentals of PGx, ensure that PGx testing meets the applicable regulatory requirements for all aspects of the clinical laboratory testing process, and follow recommendations for standardization of nomenclature and reporting.
Limited added utility of urine ethyl glucuronide compared to blood phosphatidylethanol in a predominantly transplant population
Snozek, Christine L.H. , Jannetto, Paul J. , Langman, Loralie J., Kinard, Theresa N.

Mayo Clinic

Journal of Analytical Toxicology | September 4, 2025 | Volume: 50 | Issue: 1 | Pages: No page available

10.1093/jat/bkaf084 | PMID 40910927 Get It

Abstract Background Alcohol biomarkers including ethyl glucuronide (EtG) and phosphatidylethanol (PEth) are ordered frequently in clinical and forensic settings including solid organ transplantation. PEth provides a long detection window but can be insensitive to light drinking. In contrast, EtG and ethyl sulfate (EtS) can be elevated after light alcohol consumption and might complement PEth testing. Methods Urine EtG/EtS and whole blood PEth results were evaluated from all clinically-ordered testing between 2014 and 2024. PEth and EtG/EtS confirmation were performed by liquid chromatography tandem mass spectrometry at two reference laboratories, using cutoffs: Lab A, PEth 20 ng/ml, EtG and EtS 500 and 250 ng/ml; Lab B, PEth 10 ng/ml, EtG and EtS 250 and 100 ng/ml. Only Lab B performed EtG screening by immunoassay, using a 500 ng/ml cutoff. Results Phosphatidylethanol was positive in 1269 (15.6%) of 8131 samples, compared to 769 (6.7%) confirmed EtG/EtS positives from 11 555 samples. EtG screening (n = 9668) was positive in 743 (7.7%) samples, of which 30 (4.0%) confirmed negative (false positives); the screen was indeterminate in 267 (2.8%) samples, 66 of which confirmed positive and 172 negative. Of 3132 paired PEth and EtG samples, 2887 (92.2%) were concordant, 224 (7.2%) were PEth-positive, and 21 (0.7%) were EtG-positive. PEth was significantly more sensitive in paired samples (P < .001), even after accounting for potential confounders such as transfusion. Limiting testing to PEth would have correctly identified alcohol consumption in 331 of 373 (88.7%) instances versus EtG/EtS in 149 (39.9%), and reduced charges by >$720 000 USD. Discussion Phosphatidylethanol outperformed EtG/EtS in detecting alcohol consumption in a predominantly abstinent transplant population. Compared to PEth, EtG/EtS had lower overall positivity and poorer sensitivity in paired samples; additionally, EtG screening demonstrated false positives and indeterminate results. EtG testing provided little added value beyond PEth in this population, and did not warrant the increased cost of performing both tests.
Breast Cancer Method of Detection: Frequently Asked Questions
Bahl, Manisha , Aminololama‐Shakeri, Shadi , Chen, L, Chikarmane, Sona A. , Dontchos, Brian N. , Lampen-Sachar, Katharine , Langman, Eun L. , Rosen, Eric L. , Rossi, Joanna , Ghate, Sujata V. , Dontchos, Brian N , Ojeda-Fournier, Haydee , Rossi, Joanna , Sharpe, Richard E. , Destounis, Stamatia V. , Eby, Peter R.

Mayo Clinic

Journal of Breast Imaging | July 26, 2025 | Volume: 7 | Issue: 6 | Pages: 718-728

10.1093/jbi/wbaf048 | PMID 41183368 Get It

Abstract The initial method of detection (MOD) refers to the first imaging examination, physical symptom, or clinical sign that prompts further investigation and ultimately leads to a new breast cancer diagnosis. The MOD is assigned at the patient level and falls into 1 of 3 categories: screening in asymptomatic patients, detection by patients or health care providers, or neither of the above. The MOD should be assigned prospectively by the radiologist when interpreting an examination with a final BI-RADS category of 4 or 5, before image-guided biopsy and breast cancer diagnosis. The MOD is not assigned to examinations classified as BI-RADS category 0, 1, 2, 3, or 6, nor is it assigned in the setting of an active breast cancer diagnosis. This Clinical Practice article addresses frequently asked questions and challenging clinical scenarios compiled by the American College of Radiology’s Screening and Emerging Technology Committee to guide consistent MOD assignment. For example, if a patient presents with a lump but is ultimately found to have a suspicious finding requiring biopsy in the contralateral breast, the MOD should reflect the reason for presentation, the patient-detected symptom (Pat), even if the cancer itself is asymptomatic. By increasing awareness of MOD and standardizing MOD reporting practices, radiologists can contribute to improved data collection. While MOD is not currently tracked in U.S. cancer registries, its systematic collection may offer valuable insights into screening effectiveness, technology performance, and disparities in cancer detection. Standardized MOD reporting has the potential to strengthen early detection efforts and improve outcomes across diverse clinical settings.
B-291 Validation of a Simple Qualitative Immunoassay for 21 Drugs of Abuse in Meconium on a Single Biochip Array
Lahr, Richard G. , Lightfoot, Alison, Langman, L, Jannetto, Paul J. , Sharma, Pragya

Mayo Clinic

Clinical Chemistry | October 2, 2024 | Volume: 70 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvae106.648 Get It

Abstract Background Drugs use during pregnancy is a major social and medical issue, which may lead to significant pre- and post-natal complications, such as preterm birth and newborn mortality. Exposed newborns may have long-term behavioral, cognitive, and developmental problems. Accurate detection of in utero drug exposure is crucial for timely medical intervention for the newborn and the mother. Meconium is the ‘gold standard' matrix for detection of drugs in newborn which reflects drug exposure during pregnancy. This study aims to develop and optimize a clinical assay for simultaneous screening of 21 drugs in meconium using a custom biochip array. Methods Custom biochip array (Randox Laboratories Ltd.) included 21 discrete test regions (DTRs) for amphetamine, methamphetamine, opioids/opiates (targeting morphine, oxymorphone, oxycodone, hydrocodone, 6-monoacetyl morphine, tramadol, buprenorphine, fentanyl, and methadone), phencyclidine (PCP), cocaine (targeting benzoylecgonine), benzodiazepines (targeting oxazepam, lorazepam, and clonazepam), zolpidem, barbiturates (targeting phenobarbital), ethyl glucuronide, methylphenidate, and marijuana metabolite (targeting Delta-9-Carboxy-Tetrahydrocannabinol [THC-COOH]). Patient samples were obtained from the residual meconium samples that had been previously used for other tests. Blank meconium samples were spiked at in-house cutoff, negative and positive assay control levels. All samples were extracted in specimen diluent using Biotage® Lysera and centrifuged. The supernatant was analyzed on a fully automated Randox Evidence+® Analyzer. A robotic arm pipetted 60 µL sample on to a biochip and then the analyzer performed a competitive chemiluminescent immunoassay. The results were generated as relative light units (RLUs). Results The sample results were determined to be “positive” or “negative” based on average RLU of cutoff controls for each analyte on an assay. The intra-assay (CV ≤ 15%) and inter-assay (CV ≤ 18%) precision was 100% agreement for positive and negative controls and there was no observed carryover for any of the analytes. The sample recovery was excellent with minimal to no matrix suppression for all analytes. Accuracy was performed by comparing spiked analyte results from Randox Evidence+® Analyzer with the expected results and all the spiked samples matched (positive or negative). When authentic patient or spiked results were compared with external laboratory test results, some discordant results were obtained. However, the discrepancies could be explained based on the different cutoffs (e.g., the Randox assay had lower cutoffs) or the known assay cross reactivities within the analytes of same class. These deviations did not affect clinical utility of the assay. Conclusions We validated a novel and simple qualitative chemiluminescent immunoassay in meconium using a custom biochip array. Unlike other routine screening/ELISA methods, which require separate assays for detection of similar drug targets, the custom biochip array offers a convenient, rapid and efficient method that utilizes only a single sample preparation for the screening of all 21 drug targets. Therefore, this technology has potential to be utilized as high-throughput screening assay. Like all qualitative assays, the limitation of this test is that all positive results will need to be assessed quantitatively for a definitive interpretation.
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Lemaı̂tre, F. , Barten, Markus J. , Bergan, Stein , Shipkova, Maria , Vinks, Sander, Wieland, Eberhard , Bornemann-Kolatzki, Kirsten , Brunet, Mercè , Winter, Brenda C. M. de , Ito, Taihei, Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lawson, Roland , Lloberas, Núria , Marquet, Pierre , Millán, Olga , Mizuno, Tomoyuki , Noceti, Ofelia , Oellerich, Michael , Pattanaik, Smita , Seger, Christoph , Schaik, Ron HN van , Venkataramanan, Raman , Walson, Phil, Woillard, Jean‐Baptiste , Langman, Loralie J., Masuda, Satohiro , Lemaitre, Florian, Gelder, Teun van , Vinks, Sander, Dieterlen, Maja‐Theresa , Elens, Laure , Moes, Dirk Jan A. R. , Pawiński, Tomasz , Walson, Philip D.

Mayo Clinic

Therapeutic Drug Monitoring | September 27, 2024 | Volume: 47 | Issue: 1 | Pages: 4-31

10.1097/ftd.0000000000001250 | PMID 39331837 Get It

Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.
Characterization of the alcohol biomarker phosphatidylethanol in donor whole blood and apheresis red blood cells: Implications for transfusion recipients
Kinard, Theresa N. , Alegria, Kathy N., Langman, Loralie J., Jannetto, Paul J. , Snozek, Christine L.H. , Sharma, Pragya, Sharma, Pragya

Mayo Clinic

Transfusion | July 9, 2024 | Volume: 64 | Issue: 9 | Pages: 1617-1622

10.1111/trf.17942 | PMID 38979963 Get It

AbstractIntroductionPhosphatidylethanol (PEth) is a long‐term marker of alcohol consumption used frequently in clinical scenarios such as liver transplant evaluation. Recent cases have demonstrated that packed red blood cell (pRBC) transfusion creates the potential for artificial elevation or decrease of observed PEth concentrations in recipients. Very little is known about the prevalence or stability of PEth in pRBCs.MethodsApheresis and whole‐blood (WB) donations were tested for PEth using liquid chromatography – tandem mass spectrometry with limit of quantitation 10 ng/mL. Units were stored under routine blood bank conditions to evaluate the stability of PEth and the impact of irradiation.ResultsOver 40% of apheresis and WB donors had PEth ≥10 ng/mL (maximum observed 587 ng/mL). As WB units were processed into component pRBCs, PEth concentrations increased and were higher than donor WB levels (EDTA sample) prior to collection (maximum observed 711 ng/mL). Storage for up to 5 weeks post donation resulted in mean 17.3% decrease in PEth‐positive units; in contrast to a prior report, we observed no PEth formation in units with negative (<10 ng/mL) baseline concentrations. Irradiation of pRBCs did not substantially affect PEth concentrations in either PEth‐positive or PEth‐negative units.DiscussionPEth concentrations in healthy blood donors may potentially confound alcohol use or abstinence assessment in pRBC recipients. Transfusion medicine services and clinical practices such as transplantation and behavioral medicine should recognize this phenomenon and collaborate on testing protocols to appropriately interpret PEth in pRBC recipients.
PHYOX2: Nedosiran Reduced Urinary Oxalate Excretion in Patients with Primary Hyperoxaluria
Baum, Michelle A. , Langman, Craig B. , Cochat, Pierre , Moochhala, Shabbir H. , Hamamoto, Shuzo , Satoh, Hiroyuki, Mourani, Chebl, Amrite, Aniruddha, Höppe, Bernd , Lieske, John C. , Ariceta, Gema

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: B9-B9

10.1681/asn.20213210s1b9b Get It

Laboratorian Interpretation of Drug Testing Results in Pain Management: Lessons From College of American Pathologists Proficiency Testing
Snozek, Christine L.H. , Langman, Loralie J., Dizon, Annabel, Krasowski, Matthew D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 7, 2024 | Volume: 148 | Issue: 12 | Pages: 1292-1298

10.5858/arpa.2023-0310-cp | PMID 38325407 Get It

Context.— Accurate interpretation of drug test results is key to appropriate patient care in numerous settings, including pain management. Despite recommendations that providers should consult laboratory professionals for guidance when necessary, literature demonstrating laboratorian expertise in drug test interpretation is lacking. Objective.— To evaluate participating laboratories’ performance on the case-based, interpretive (“dry”) challenge included with each Drug Monitoring for Pain Management proficiency testing program from 2012–2023. Design.— All challenges (n = 23) required participants to identify if drug test results were consistent or inconsistent with prescribed medications in the case history. Relevant medications, presumptive and confirmatory drug test results, and participant responses were extracted from program summary reports and examined for performance and common themes. Results.— Overall, 91.8% (6821 of 7431) of participant responses correctly identified whether drug testing was consistent with medications. There were 8 challenges with participant scores less than 91.8% (range, 59.8% [49 of 82 responses] to 88.9% [193 of 217 responses]). Common knowledge gaps identified in these challenges included false-positive presumptive (screening) results, minor metabolism of opiates, and recognizing that presence of a nonprescribed drug is inconsistent with prescribed medications. Although some participants repeatedly responded incorrectly, there were no associations between laboratory type, personnel responding, or analytical performance and incorrect responses to interpretative challenges. Conclusions.— Program participants performed well overall, but several concerning educational gaps were identified. Laboratorians have a role in providing interpretative guidance for drug testing and should emphasize ongoing education to ensure competence in the setting of constantly changing prescribed and nonprescribed drug use.